Methods and compositions for treating allergic ocular diseases

Abstract

The present disclosure provides methods for the treatment of an allergic ocular disease (e.g., allergic conjunctivitis, keratoconjunctivitis, or giant papillary conjunctivitis). In particular, the present disclosure provides methods for the treatment of an allergic ocular disease through administration of antibodies that bind to human Siglec-8 or compositions comprising said antibodies. The present disclosure also provides articles of manufacture or kits comprising antibodies that bind to human Siglec-8 for the treatment of an allergic ocular disease.

1 . A method for treating or preventing an allergic ocular disease in an individual comprising administering to the individual an effective amount of a composition comprising an antibody that binds to human Siglec-8. 
     
     
         2 . The method of  claim 1 , wherein the individual has allergic conjunctivitis or giant papillary conjunctivitis. 
     
     
         3 - 7 . (canceled) 
     
     
         8 . The method of  claim 2 , wherein the individual uses contact lenses. 
     
     
         9 . The method of  claim 1 , wherein the individual has increased inflammation in at least a portion of the conjunctiva, as compared to an individual without an allergic ocular disease. 
     
     
         10 . The method of  claim 9 , wherein the individual has an increased number of mast cells, neutrophils, eosinophils, and/or lymphocytes in at least a portion of the conjunctiva, as compared to an individual without an allergic ocular disease. 
     
     
         11 . The method of  claim 1 , wherein;
 (a) a conjunctival scraping obtained from the individual comprises eosinophils;   (b) a serum or tear sample obtained from the individual has increased IgE, as compared to an individual without an allergic ocular disease: or   (c) an epicutaneous or intracutaneous allergy test administered to the individual using an allergen results in an allergic response.   
     
     
         12 . (canceled) 
     
     
         13 . (canceled) 
     
     
         14 . The method of  claim 1 , wherein:
 (a) one or more symptom(s) in the individual are reduced as compared to a baseline level before administration of the composition; or   (b) one or more of conjunctival itching, conjunctival redness, conjunctival swelling, ocular discharge, ulceration, tearing, lid hypertrophy, crusting, symblepharon, periocular eczema, madarosis, photophobia, keratitis, giant papillae, and cataracts in the individual are reduced as compared to a baseline level before administration of the composition.   
     
     
         15 . (canceled) 
     
     
         16 . The method of  claim 1 , wherein the composition is administered by intravenous infusion or subcutaneous injection. 
     
     
         17 . (canceled) 
     
     
         18 . The method of  claim 1 , wherein the antibody comprises a Fc region and N-glycoside-linked carbohydrate chains linked to the Fc region, wherein less than 50% of the N-glycoside-linked carbohydrate chains of the antibody in the composition contain a fucose residue. 
     
     
         19 . The method of  claim 18 , wherein substantially none of the N-glycoside-linked carbohydrate chains of the antibody in the composition contain a fucose residue. 
     
     
         20 . The method of  claim 1 , wherein the antibody comprises a heavy chain comprising a heavy chain variable region and a light chain comprising a light chain variable region, and wherein:
 (A) the heavy chain variable region comprises (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:61, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:62, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO:63, and the light chain variable region comprises (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:64, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:65, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:66;   (B) the heavy chain variable region comprises (i) HVR-H1 comprising the amino acid sequence of SEO ID NO:61, (ii) HVR-H2 comprising the amino acid sequence of SEO ID NO:62, and (iii) HVR-H3 comprising the amino acid sequence selected from SEO ID NOs:67-70, and the light chain variable region comprises (i) HVR-L1 comprising the amino acid sequence of SEO ID NO:64, (ii) HVR-L2 comprising the amino acid sequence of SEO ID NO:65, and (iii) HVR-L3 comprising the amino acid sequence of SEO ID NO:71;   (C) the heavy chain variable region comprises the amino acid sequence of SEO ID NO:6, and the light chain variable region comprises the amino acid sequence of SEO ID NO:16 or 21;   (D) the heavy chain variable region comprises an amino acid sequence selected from SEO ID NOs:11-14, and the light chain variable region comprises an amino acid sequence selected from SEO ID NOs:23-24;   (E) the heavy chain variable region comprises an amino acid sequence selected from SEO ID NOs:2-14, and the light chain variable region comprises an amino acid sequence selected from SEO ID NOs:16-24;   (F) the heavy chain variable region comprises an amino acid sequence selected from SEO ID NOs:2-10, and the light chain variable region comprises an amino acid sequence selected from SEO ID NOs:16-22;   (G) the heavy chain variable region comprises (i) HVR-H1 comprising the amino acid sequence of SEO ID NO:88, (ii) HVR-H2 comprising the amino acid sequence of SEO ID NO:91, and (iii) HVR-H3 comprising the amino acid sequence of SEO ID NO:94, and the light chain variable region comprises (i) HVR-L1 comprising the amino acid sequence of SEO ID NO:97, (ii) HVR-L2 comprising the amino acid sequence of SEO ID NO:100, and (iii) HVR-L3 comprising the amino acid sequence of SEO ID NO:103;   (H) the heavy chain variable region comprises (i) HVR-H1 comprising the amino acid sequence of SEO ID NO:89, (ii) HVR-H2 comprising the amino acid sequence of SEO ID NO:92, and (iii) HVR-H3 comprising the amino acid sequence of SEO ID NO:95, and the light chain variable region comprises (i) HVR-L1 comprising the amino acid sequence of SEO ID NO:98, (ii) HVR-L2 comprising the amino acid sequence of SEO ID NO:101, and (iii) HVR-L3 comprising the amino acid sequence of SEO ID NO:104;   (I) the heavy chain variable region comprises (i) HVR-H1 comprising the amino acid sequence of SEO ID NO:90, (ii) HVR-H2 comprising the amino acid sequence of SEO ID NO:93, and (iii) HVR-H3 comprising the amino acid sequence of SEO ID NO:96, and the light chain variable region comprises (i) HVR-L1 comprising the amino acid sequence of SEO ID NO:99, (ii) HVR-L2 comprising the amino acid sequence of SEO ID NO:102, and (iii) HVR-L3 comprising the amino acid sequence of SEO ID NO:105;   (J) the heavy chain variable region comprises the amino acid sequence of SEO ID NO:106, and the light chain variable region comprises the amino acid sequence of SEO ID NO:109;   (K) the heavy chain variable region comprises the amino acid sequence of SEO ID NO:107, and the light chain variable region comprises the amino acid sequence of SEO ID NO:110;   (L) the heavy chain variable region comprises the amino acid sequence of SEO ID NO:108, and the light chain variable region comprises the amino acid sequence of SEO ID NO:111;   (M) the heavy chain comprises the amino acid sequence of SEO ID NO:75, and the light chain comprises the amino acid sequence of SEO ID NO:76; or   (N) the heavy chain comprises the amino acid sequence of SEO ID NO:75, and the light chain comprises the amino acid sequence of SEO ID NO:77.   
     
     
         21 - 26 . (canceled) 
     
     
         27 . The method of  claim 1 , wherein the antibody comprises:
 (a) heavy chain variable region comprising:
 (1) an HC-FR1 comprising the amino acid sequence of SEQ ID NO:26; 
 (2) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:61; 
 (3) an HC-FR2 comprising the amino acid sequence of SEQ ID NO:34; 
 (4) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:62; 
 (5) an HC-FR3 comprising the amino acid sequence of SEQ ID NO:38; 
 (6) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:63; and 
 (7) an HC-FR4 comprising the amino acid sequence of SEQ ID NOs:45; and 
   (b) a light chain variable region comprising:
 (1) an LC-FR1 comprising the amino acid sequence of SEQ ID NO:48; 
 (2) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:64; 
 (3) an LC-FR2 comprising the amino acid sequence of SEQ ID NO:51; 
 (4) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:65; 
 (5) an LC-FR3 comprising the amino acid sequence of SEQ ID NO:55 or 58; 
 (6) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:66; and 
 (7) an LC-FR4 comprising the amino acid sequence of SEQ ID NO:60. 
   
     
     
         28 - 44 . (canceled) 
     
     
         45 . The method of  claim 20 , wherein the antibody is a humanized antibody or a chimeric antibody. 
     
     
         46 . The method of  claim 20 , wherein the antibody depletes blood eosinophils and inhibits mast cell activation. 
     
     
         47 . The method of  claim 20 , wherein the antibody comprises a heavy chain Fc region comprising a human IgG Fc region. 
     
     
         48 . The method of  claim 47 , wherein the human IgG Fc region comprises a human IgG1 or human IgG4 Fc region. 
     
     
         49 . The method of  claim 48 , wherein the human IgG1 Fc region is non-fucosylated. 
     
     
         50 . (canceled) 
     
     
         51 . The method of  claim 48 , wherein the human IgG4 Fc region comprises the amino acid substitution S228P, wherein the amino acid residues are numbered according to the EU index as in Kabat. 
     
     
         52 . The method of  claim 20 , wherein the antibody has been engineered to improve antibody-dependent cell-mediated cytotoxicity (ADCC) activity. 
     
     
         53 . (canceled) 
     
     
         54 . The method of  claim 20 , wherein at least one or two of the heavy chains of the antibody is non-fucosylated. 
     
     
         55 . (canceled) 
     
     
         56 . The method of  claim 1 , wherein the antibody is a monoclonal antibody. 
     
     
         57 . The method of  claim 1 , wherein the composition is administered in combination with one or more additional therapeutic agent(s) for treating or preventing an allergic ocular disease. 
     
     
         58 . The method of  claim 57 , wherein the one or more additional therapeutic agent(s) are selected from the group consisting of a corticosteroid, antihistamine, ketotifen, azelastine, epinastine, bepostatine, cyclosporine, and a non-steroidal anti-inflammatory agent (NSAID). 
     
     
         59 . The method of  claim 1 , wherein the individual is a human. 
     
     
         60 . The method of  claim 1 , wherein the composition is a pharmaceutical composition comprising the antibody and a pharmaceutically acceptable carrier. 
     
     
         61 . (canceled)